



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman		FILING DATE September 19, 2003		
				GROUP 1615				
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
9/8	A.A	4 0 7 9 0 3 8	03/14/78	Choi et al	260	47	03/05/76	
	A.B	4 0 9 3 7 0 9	06/06/78	Choi et al	424	19	01/28/75	
	A.C	4 1 3 1 6 4 8	12/26/78	Choi et al	424	22	03/02/78	
	A.D	4 1 3 8 3 4 4	02/06/79	Choi et al	252	1	08/24/77	
	A.E	4 1 8 0 6 4 6	12/25/79	Choi et al	528	153	03/03/78	
	A.F	4 3 0 4 7 6 7	12/08/81	Heller et al	424	78	05/15/80	
	A.G	4 9 4 6 9 3 1	08/07/90	Heller et al	528	320	06/14/89	
	A.H	5 2 9 4 6 0 4 5 4 2 0 4 6 0	03/15/94	Nussenblatt et al	514	11	12/20/89	
	A.I	5 3 8 7 5 8 9	02/07/95	Kulkarni	514	291	11/17/92	
	A.J	5 4 1 1 9 6 2	05/1995	Kaswan				
9/8	A.K	5 4 5 7 1 8 2	10/10/95	Wiederrecht et al	530	402	02/15/94	
	FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)	
	9/8	A.L	WO 00/66122	11/09/00	PCT WO	A61K	31/436	N/A
		A.M	WO 02/085928	10/31/02	PCT WO	C07K	7/54	Abstract only
		A.N	WO 2004/014373	02/19/04	PCT WO	A61K	31/436	N/A
		A.O	EP 1074255	02/07/01	EP	A61K	31/40	N/A
		A.P	WO 99/34830	07/15/99	PCT WO	A61K	47/18	N/A
	A.Q	AU 47386/88	Unknown	AU	NO DATE	Unknown	N/A	
	OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
9/8	A.R	Algvere et al, <u>Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD</u> , European J of Ophthalmology (1999), 9(3):217-230						
	A.S	Anderson et al., <u>A Role for Local Inflammation in the Formation of Drusen in the Aging Eye</u> , American Journal of Ophthalmology, Vol. 134, No. 3, September 2002, pp. 411-431						
	A.T	Apel et al., <u>A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy</u> , Curr. Eye Res. 14:659-667, 1995						
EXAMINER				DATE CONSIDERED				
				02/23/06				
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.								

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161							
				INFORMATION DISCLOSURE STATEMENT BY APPLICANT									
				APPLICANT Gholam Peyman		FILING DATE September 19, 2003		GROUP 1615					
(37 CFR 1.98(b))				(Use several sheets if necessary)									
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	B.A	5	7	7	0	6	0	7	06/23/98	Honbo et al	514	302	07/18/94
	B.B	5	7	7	3	0	1	9	06/30/98	Ashton et al	424	423	09/27/95
	B.C	5	9	5	2	3	7	1	09/14/99	Baker et al	514	443	10/08/97
	B.D	5	9	6	8	5	4	3	10/19/99	Heller et al	424	425	12/05/97
	B.E	6	0	0	4	5	6	5	12/21/99	Chiba	424	278.1	09/23/97
	B.F	6	3	3	1	3	1	3	12/2001	Wong et al	—	—	
	B.G	6	3	5	0	4	4	2	02/26/02	Garst	424	78.04	05/30/2001
	B.H	6	4	6	2	0	7	1	10/2002	Castillejos	—	—	
	B.I	6	4	8	2	7	9	9	11/2002	Tuse et al	—	—	
	B.J	6	5	0	6	2	0	6	07/22/03	Nelson et al	424	426	08/04/00
JS	B.K	6	5	3	4	6	9	3	03/18/03	Fischell et al.	A61F	13/00	01/31/01
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS													
		DOCUMENT NUMBER							PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L	ALL 20350/92							Unknown	ALL NO DATE		Unknown	N/A
JS	B.M	CN 1333018							01/30/02	CN	A61K	9/06	Abstract only
	B.N	CN 1340358							03/20/02	CN	A61K	38/13	Abstract only
	B.O	CN 1456350							11/19/03	CN	A61K	9/00	Abstract only
	B.P	DE 19810655							09/16/99	DE	A61K	38/13	Abstract only
JS	B.Q	EP 1142566							10/10/01	EP	A61K	9/08	Abstract only
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
JS	B.R	Aramant et al, <u>Retinal transplantation</u> , Science & Medicines (2000), 7:20-29											
JS	B.S	Carmo et al, <u>Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotocin-induced diabetes</u> , Mediators of Inflammation (2000), 9(5):243-248											
JS	B.T	Chiou, <u>Topical Treatment of Ocular Hypertension, Glaucoma, Ischemic Retinopathy and Age-Related Macular Degeneration with Ophthalmic Formulation of Dopamine Antagonists</u> , U.S. Patent Application Publication No. US 203/0069232, published 04/10/03											
EXAMINER Gholam Peyman									DATE CONSIDERED 02/23/06				
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.													

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman									
				FILING DATE September 19, 2003		GROUP 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER			ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
OS	C.A	6	6	1	3	3	5	5	09/02/03	Ng et al	424	462	05/11/01
/	C.B	6	6	1	7	3	4	5	09/09/03	Gregory et al	514	395	09/12/00
/	C.C	6	6	6	7	3	7	1	12/23/03	Ng et al	525	462	11/14/02
/	C.D	6	6	7	0	3	9	8	12/2003	Edwards et al	—	—	
/	C.E	6	6	7	3	8	0	7	01/2004	Sakai et al	—	—	
OS	C.F	6	7	1	3	0	8	1	03/2004	Robinson et al	—	—	
	C.G												
	C.H												
	C.I												
	C.J												
	C.K												
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS													
		DOCUMENT NUMBER			PUBLICATION DATE		COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS	TRANSLATION (YES/NO)		
OS	C.L	JP 10-218787			08/18/98		JP		A61K	38/22	Yes		
/	C.M	JP 1997030966			02/04/97		JP		A61K	31/365	Yes		
/	C.N	JP 2001-064198			03/13/01		JP		A61K	38/22	Yes		
/	C.O	WO 02/24234			03/28/02		PCT WO		A61K	48/00	N/A		
/	C.P	WO 03/051385			06/26/03		PCT WO		A61K	38/13	Abstract only		
OS	C.Q	WO 03/017990			03/06/03		PCT WO		A61K	31/00	N/A		
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
OS	C.R	Ciciarelli et al, Pharmacokinetics of subconjunctivally administered cyclosporine A. Local delivery prior to chemotherapy for retinoblastoma, IOVS (3/15/2001), 42(4):S332											
OS	C.S	Costantini LC, et al., Immuophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture, Experimental Neurology 164,60-60 (2000)											
OS	C.T	Das et al, The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study, Experimental Neurology (1999), 157:58-68											
EXAMINER							DATE CONSIDERED						
							02/23/06						
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.													

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
(37 CFR 1.98(b))				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
OS	D.L	WO 2004/096261	11/11/04	PCT WO	A61K	38/13	Abstract only
	D.M	WO 2004/043480	05/27/04	PCT WO	A61K	38/00	N/A
	D.N	WO 2005/030205	04/07/05	PCT WO	A61K	31/436	N/A
	D.O	WO 2005/011813	02/10/05	PCT WO	A61P	27/02	N/A
	D.P	WO 89/01772	03/09/89	PCT WO	A61K	9/00	N/A
OS	D.Q	WO 99/42104	08/26/99	PCT WO	A61K	31/435	N/A
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
OS	D.R	Del Cerro et al, <u>Histologic correlation of human neural retinal transplantation</u> , Invest. Ophthalmology & Visual Science (2000), 41(10):3142-3148					
OS	D.S	Donnenfeld et al., <u>Cyclosporine provides effective treatment for dry eye</u> , Therapeutic Updates in Ophthalmology, Special Issue, July 1999, pp. 1-3					
OS	D.T	Enyedi et al, <u>Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and dexamethasone (DEX)</u> , Invest. Ophthalmology and Visual Science, Vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994, abstract					
EXAMINER <i>Gholam Peyman</i>				DATE CONSIDERED <i>02/23/06</i>			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/25SERIAL NO.
10/667,161INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Gholam PeymanFILING DATE
September 19, 2003GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A.						
	E.B.						
	E.C.						
	E.D.						
	E.E.						
	E.F.						
	E.G.						
	E.H.						
	E.I.						
	E.J.						
	E.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L.						
	E.M.						
	E.N.						
	E.O.						
	E.P.						
	E.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	E.R.	Enyedi et al, <u>An intravitreal device providin sustained release of cyclosporine and dexamethasone</u> , Curr. Eye Res. May 1996, Vol. 15, No. 5, pp. 549-557
	E.S.	Garweg et al, <u>Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine</u> , Klinische Monatsblätter für Augenheilkunde, Vol., 199, No. 3, September 1991, pp. 199-205
	E.T.	Gilbard, <u>EW Interview: Electrolyte balance is key to dry-eye product's success</u> , EyeWorld, February 2000, pp. 20ff

EXAMINER

DATE CONSIDERED

02/23/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman		FILING DATE September 19, 2003	
(37 CFR 1.98(b))				GROUP 1615			

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A						
	F.B						
	F.C						
	F.D						
	F.E						
	F.F						
	F.G						
	F.H						
	F.I						
	F.J						
	F.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L						
	F.M						
	F.N						
	F.O						
	F.P						
	F.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)	
	F.R. Grisolano et al., <u>Retinal Toxicity Study of Intravitreal Cyclosporin</u> , Ophthalmic Surgery, March 1986, 17:155-156
	F.S. Hageman et al., <u>Diagnostics and Therapeutics for Macular Degeneration-Related Disorders</u> , U.S. Patent Application Publication No. US 2002/0015957, published 02/07/02,
	F.T. Jiang et al., <u>Corneal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats</u> , Invest. Ophthalmology & Visual Science (1994), 35(13):4300-4308

EXAMINER 	DATE CONSIDERED <div style="font-size: 1.5em; font-family: cursive;">02/23/06</div>
--------------	--

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A.						
	G.B.						
	G.C.						
	G.D.						
	G.E.						
	G.F.						
	G.G.						
	G.H.						
	G.I.						
	G.J.						
	G.K.						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L.						
	G.M.						
	G.N.						
	G.O.						
	G.P.						
	G.Q.						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
Q/S	G.R.	Karacortu et al., <u>Lack of toxicity of intravitreally administered interferon Alpha-2a</u> , Ophthalmic Surger (1999), 23:833-35					
Q/S	G.S.	Keep et al., <u>Introduction: Immunosuppressants as Neuroprotective Agents</u> Immunosuppressant Analogs in Neuroprotection, Part I: Immunosuppressants, Neurologic Disorders, and Neuroprotection, Ed: Borlongan & Sanberg, Humana Press Inc., Totowa, NJ, pp.3-32 (11/2002)					
Q/S	G.T.	Kiryu et al., <u>In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury</u> , Poster Presentation 1247-B128 (03/1998)					
EXAMINER Ammara Y. Sheikh				DATE CONSIDERED 02/23/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/25SERIAL NO.
10/667,161INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Gholam PeymanFILING DATE
September 19, 2003GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A.						
	H.B.						
	H.C.						
	H.D.						
	H.E.						
	H.F.						
	H.G.						
	H.H.						
	H.I.						
	H.J.						
	H.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L.						
	H.M.						
	H.N.						
	H.O.						
	H.P.						
	H.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	H.R.	Lai et al, <u>Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer</u> , IOVS (9/2000), 41(10):3134-3141
	H.S.	Lallemant et al., <u>Cyclosporine A delivery to the eye: A pharmaceutical challenge</u> , European Journal of Pharmaceutics and Biopharmaceutics, 45 (2003), pp. 307-318
	H.T.	Lipner, <u>Dry Eye 101: Developing etiologies and treatments for this widespread syndrome</u> , EyeWorld, February 1999, pp. 19ff






EXAMINER

DATE CONSIDERED

02/23/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.




Substitute Disclosure Form (PTO-1449)


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	I.A						
	I.B						
	I.C						
	I.D						
	I.E						
	I.F						
	I.G						
	I.H						
	I.I						
	I.J						
	I.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	I.L						
	I.M						
	I.N						
	I.O						
	I.P						
	I.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	I.R	Lipper et al., <u>Recent therapeutic advances in dermatology</u> , JAMA, Vol. 283, No. 2, January 12, 2000, pp, 175-177					
	I.S	Lopez et al, <u>Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS</u> , Invest. Ophthalmology & Visual Science (1989). 30:586-588					
	I.T	Lund et al, <u>Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats</u> , PNCS (2001), 98(17):9942-9947					
EXAMINER				DATE CONSIDERED			
							
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman		FILING DATE September 19, 2003	
(37 CFR 1.98(b))				GROUP 1615			



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	J.A						
	J.B						
	J.C						
	J.D						
	J.E						
	J.F						
	J.G						
	J.H						
	J.I						
	J.J						
	J.K						


FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	J.L						
	J.M						
	J.N						
	J.O						
	J.P						
	J.Q						





OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	J.R	Martin DF et al., <u>Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune Uveoretinitis</u> , The Journal of Immunology, 1995, 154:922-927
	J.S	Nicoletti et al, <u>The effects of deoxysperqualin on the development of diabetes in diabetes-prone BB rats</u> , Scandinavian Journal of Immunology (1992), 36(3):415-420
	J.T	Passos et al, <u>Ocular Toxicity of Intravitreal Tacrolimus</u> , phthlamic Surgery and Lasers, March/April 2002, Vol. 33, No. 2, pp.140-144


EXAMINER 	DATE CONSIDERED 02/23/06
---	-----------------------------


EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	K.A.						
	K.B.						
	K.C.						
	K.D.						
	K.E.						
	K.F.						
	K.G.						
	K.H.						
	K.I.						
	K.J.						
	K.K.						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	K.L.						
	K.M.						
	K.N.						
	K.O.						
	K.P.						
	K.Q.						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
2/8	K.R.	PCT, <u>International Search Report</u> , PCT/2004/024054, mailed 07/27/04, 7 pg.					
2/8	K.S.	PCT, <u>International Search Report</u> , PCT/US03/28315, mailed 06/15/04, 6 pages					
2/8	K.T.	Peyman et al, <u>Keratitis (Noninfectious)</u> . Principles and Practice of Ophthalmology, W.B. Saunders Company, 1980, pp.446-449					
EXAMINER				DATE CONSIDERED			
							
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
(37 CFR 1.98(b))				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
	LB						
	LC						
	LD						
	LE						
	LF						
	LG						
	LH						
	LI						
	LJ						
	LK						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	LL						
	LM						
	LN						
	LO						
	LP						
	LQ						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
OS	LR	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063997, published 03/24/05, Serial No. 10/752,124, filed 01/06/04					
OS	LS	Peyman et al., <u>Intravitreal Surgery: Principles and Practice</u> , 2nd Edition, 1994, Apleton & Lange, CT, pp. 443-452					
OS	LT	Peyman et al., <u>Implantation of a sustained-release ganciclovir implant</u> , Vitreoretinal Surgical Techniques, Martin Dunitz Ltd., 2001, Chapter 45, pp. 521-531					
EXAMINER				DATE CONSIDERED			
				02/23/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
(37 CFR 1.98(b))				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	M.A.						
	M.B.						
	M.C.						
	M.D.						
	M.E.						
	M.F.						
	M.G.						
	M.H.						
	M.I.						
	M.J.						
	M.K.						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	M.L.						
	M.M.						
	M.N.						
	M.O.						
	M.P.						
	M.Q.						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	M.R.	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03					
	M.S.	Peyman et al., <u>Intravitreal drug therapy</u> , Japanese Journal of Ophthalmology (1989, 33(4):392-404					
	M.T.	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2004/0092435, published 05/13/04, Serial No. 10/289,772, filed 11/07/02					
EXAMINER				DATE CONSIDERED			
				02/23/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25		SERIAL NO. 10/667,161	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	N.A						
	N.B						
	N.C						
	N.D						
	N.E						
	N.F						
	N.G						
	N.H						
	N.I						
	N.J						
	N.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	N.L						
	N.M						
	N.N						
	N.O						
	N.P						
	N.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
Q/S	N.R	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063996, published 03/24/05, Serial No. 10/667,161, filed 09/19/03					
Q/S	N.S	Revill et al., <u>Genetically Engineered Analogs of Ascomycin for Nerve Regeneration</u> , Journal of Pharmacology and Experimental Therapeutics, Vol. 302:1278-1285 (2002)					
Q/S	N.T	Shen et al, <u>Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina</u> , Archives of Ophthalmology (7/2001), 119(7):1033-1043					
EXAMINER				DATE CONSIDERED			
				02/23/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/25	SERIAL NO. 10/667,161		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE September 19, 2003		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	O.A						
	O.B						
	O.C						
	O.D						
	O.E						
	O.F						
	O.G						
	O.H						
	O.I						
	O.J						
	O.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	O.L						
	O.M						
	O.N						
	O.O						
	O.P						
	O.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
OS	O.R	Stosic-Grujic et al, <u>Leflunomide protects mice from multiple low dose streptozotocin (MLD-SA)-induced insulinitis and diabetes</u> , Clinical & Experimental Immunology (1999), 117(1):44-50					
OS	O.S	Ueno, <u>Use of Macrolide Compounds for the Treatment of Dry Eye</u> , U.S. Patent Application Publication 20030130301, published 07/10/03, Serial No. 10/354,083, filed 01/30/03					
OS	O.T	Wakelee-Lynch, <u>Interferon may offer first drug therapy for diabetic retinopathy</u> , Diabetes Care (1992), 15(2):300-301					
EXAMINER 				DATE CONSIDERED 02/23/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							